Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement

Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore. Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF and APRIL being studied for the treatment of Immunoglobulin A nephropathy and other B cell-mediated diseases. Under the terms of the agreement, Vertex will receive an upfront

Yahoo | January 11, 2025

Zai Lab inks strategic partnership with Medilink Therapeutics

More on Zai Lab

• Zai Lab: Rapidly Improving Outlook Bodes Well For The Future
• Zai Lab announces proposed public offering of American Depositary Shares
• Seeking Alpha | January 10, 2025

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

SHANGHAI & CAMBRIDGE, Mass. & BOSTON, January 10, 2025--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and

Yahoo | January 10, 2025

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

BOSTON & SHANGHAI & CAMBRIDGE, Mass., January 10, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and

Yahoo | January 10, 2025

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

SHANGHAI & SUZHOU, China & CAMBRIDGE, Mass., January 09, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink") to use MediLink’s TMALIN® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab.

Yahoo | January 9, 2025

Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock?

Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | December 24, 2024

Zai Lab (NASDAQ:ZLAB) shareholders have endured a 59% loss from investing in the stock three years ago

While not a mind-blowing move, it is good to see that the Zai Lab Limited ( NASDAQ:ZLAB ) share price has gained 24% in...

Yahoo | December 23, 2024

Zai Lab Announces Participation in Investor Conference in January 2025

SHANGHAI & CAMBRIDGE, Mass., December 12, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2025:

Yahoo | December 12, 2024

Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint

Zai Lab (ZLAB) and Novocure (NVCR) announced that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival, or mOS, versus control. PANOVA-3 evaluated the use of Tumor Treating Fields, or TTFields, therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. In the intent-to-treat population, patients treated with TTFields ther

Yahoo | December 3, 2024

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients

On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. The pivotal trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. Also Read: FDA Approves NovoCure’s Portable D

Yahoo | December 2, 2024